Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology

Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Eu2P - European programme in Pharmacovigilance and Pharmacoepidemiology. Eu2P is a European online education and training programme in pharmacovigilance and pharmacoepidemiology that delivers Master and PhD diplomas, and on-the-job training continuing education certificates or short courses. Eu2P is a unique partnership of seven Universities, fifteen pharmaceutical companies, the French and the European medicines agencies. Eu2P is funded by the EU and the EFPIA through the Innovative Medicines Initiative. - Eu2P academic partners Université Bordeaux Segalen - France Erasmus Universitair Medisch Centrum - The Netherlands Fundació Institut Catalá de Farmacologia - Universitat Autonoma de Barcelona - Spain University of Hertfordshire - United Kingdom Universita di Verona - Italy Utrecht Universiteit - The Netherlands Karolinska Institutet - Sweden - Eu2P regulatory partners EMA (European Medicines Agency) - United Kingdom ANSM (Agence nationale de sécurité du médicament et des produits de santé) - France - Eu2P industrial partners F. Hoffmann-La Roche Ltd - Switzerland Amgen NV - Belgium AstraZeneca AB - United Kingdom Bayer HealthCare - Germany Boehringer Ingelheim International GmbH - Germany Eli Lilly and Company Limited - United Kingdom GlaxoSmithKline Research and Development Ltd - United Kingdom H. Lundbeck A/S - Denmark Janssen Pharmaceutica NV - Belgium Laboratorios Almirall SA - Spain Novartis Pharma AG - Switzerland Novo Nordisk A/S - Denmark Orion Corporation - Finland Sanofi-aventis Recherche et Développement - France UCB Pharma SA - Belgium